1A
1AI.AU Algorae Pharmaceuticals Ltd
- Market cap
- AUD 20.3M
- P/E
- -
- P/B
- 4.76x
- ROE
- -63.6%
- Dividend yield
- -
- Fundamental score
- 0.7/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is 1AI.AU undervalued?
Graham numberThe Graham number of Algorae Pharmaceuticals Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Algorae Pharmaceuticals Ltd fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-63.6%), below 10%.
ROA 0/1
Return on assets (-61.1%) is below the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-221.1%) is below the industry median (-5.3%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 1/2
Cash covers 1.5 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (4.8x) is above the industry median (4.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Algorae Pharmaceuticals Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Algorae Pharmaceuticals Ltd
Algorae Pharmaceuticals Limited, an AI-enabled pharmaceutical development company, engages in the research and development of living cells technologies primarily in Australia and New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingr…
Full company profileAlgorae Pharmaceuticals Ltd financial statements
Algorae Pharmaceuticals Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 115K | 9.11K | 9.77K | 3.17K | 268K | 3.41K | 42.0K | 125K | 141K | - |
| Gross Profit | 115K | 121K | 9.77K | 3.17K | -49.3K | -743.00 | -557.00 | - | - | - |
| Operating Income | -5.18M | -4.21M | -4.11M | -3.15M | -2.28M | -2.38M | -2.13M | -2.20M | -1.69M | -3.14M |
| EBITDA | -4.14M | -514K | -3.43M | -1.27M | -1.86M | -2.38M | -2.13M | -2.10M | -1.54M | -3.14M |
| Net Income | -4.09M | -374K | -3.18M | -968K | -1.46M | -1.96M | -2.11M | -2.10M | -803K | -2.71M |
| EPS | -0.01 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 8.69M | 7.61M | 5.76M | 3.39M | 1.64M | 4.27M | 4.21M | 5.49M | 2.40M | 4.44M |
| Total Liabilities | 1.18M | 473K | 1.62M | 513K | 265K | 239K | 450K | 178K | 170K | 177K |
| Shareholders' Equity | 7.52M | 7.14M | 4.14M | 2.88M | 1.38M | 4.03M | 3.76M | 3.01M | 2.23M | 4.26M |
| Cash & Short-term Investments | 7.53M | 6.86M | 4.91M | 2.96M | 1.61M | 7.24M | 6.13M | 3.11M | 2.32M | 3.94M |
| Total Debt | - | - | 255K | 255K | - | - | - | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -3.37M | -3.57M | -1.99M | -3.11M | -1.46M | -2.04M | -1.99M | -1.52M | -785K | -2.60M |
| Capital Expenditure | 249K | 2.99K | 10.3K | 5.00 | 3.00 | 3.80K | 1.00 | 1.00 | 0.00 | 0.00 |
| Free Cash Flow | -3.62M | -3.57M | -2.00M | -3.11M | -1.46M | -2.05M | -1.99M | -1.52M | -785K | -2.60M |
| Ratios | ||||||||||
| ROE | -54.4% | -5.2% | -76.9% | -33.6% | -106.1% | -48.5% | -56.0% | -69.5% | -36.0% | -63.6% |
| ROA | -47.0% | -4.9% | -55.2% | -28.6% | -88.9% | -45.8% | -50.0% | -38.2% | -33.5% | -61.1% |
| Net Profit Margin | -3,548.1% | -4,113.0% | -32,565.9% | -30,570.4% | -544.6% | -57,398.8% | -5,015.8% | -1,673.8% | -569.3% | - |
| Debt to Equity | - | - | 0.06x | 0.09x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Algorae Pharmaceuticals Ltd dividends
Algorae Pharmaceuticals Ltd has not paid dividends in the last 10 fiscal years.
Last stock split: 81:80 on Mar 23, 2023.
Who owns Algorae Pharmaceuticals Ltd
- Insiders 33.11%
- Institutions 0.00%
- Public & others 66.89%
- Shares outstanding 2.03B
- Free float 1.38B
Algorae Pharmaceuticals Ltd company profile
- Company name
- Algorae Pharmaceuticals Ltd
- Ticker
- 1AI.AU
- ISIN
- AU000000LCT6
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- Rialto South Tower, Melbourne, VIC, Australia, 3000
- Phone
- 61 2 9698 5414
- Website
- algoraepharma.com
About Algorae Pharmaceuticals Ltd
Algorae Pharmaceuticals Limited, an AI-enabled pharmaceutical development company, engages in the research and development of living cells technologies primarily in Australia and New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient for the treatment of cardiovascular disease, such as hypertension; and NTCELL, an alginate coated capsule product for the treatment of Parkinson's disease. It is also developing AlgaraeOS in partnership with the University of New South Wales, a drug discovery platform that uses artificial intelligence protocols and big data analytics for drug discovery and development; and AlgoraeRx, a commercial pharmaceutical division that source generic and specialty medicines from manufacturers. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. Algorae Pharmaceuticals Limited was founded in 1987 and is based in Melbourne, Australia.
Algorae Pharmaceuticals Ltd management
7- Mr. David Richard HainsworthCEO & Executive Chairman · born 1973
- Mr. David GullandCOO & Director
- Mr. Vishal ShahChief Commercial Officer
- Dr. James A. MckennaChief Scientific Officer
- Mr. Waleed ElsayedHead of Sales
- Dr. Carolyn M. Sue A.M., B.S., Ph.D.Member of Medical Advisory Board & Chief Medical Officer of NTCELL · born 1964
- Ms. Catherine EarlieJoint Company Secretary